Lipid Nanoparticle Delivery With pH-Sensitive Endosomal Escape
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lipid nanoparticle drug delivery systems face challenges in efficiently delivering large, anionic nucleic acids like siRNAs and mRNA to the cytosol due to their impermeability, fragility, rapid degradation, and immunogenicity, necessitating high doses and improved delivery efficacy with reduced toxicity.
Innovation Solution
A pH-sensitive, membrane-destabilizing polymer, such as T1-L-[PEGMA m -M2 n ]-[DMAEMA q -PAA r -BMA s ] w, is used in conjunction with lipid nanoparticles to facilitate targeted delivery of therapeutic or diagnostic agents to the cytosol of target cells, enhancing delivery efficacy and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of nucleic acids are administered to overcome impermeability and degradation, then delivery efficacy is improved, but toxicity increases and immune response is stimulated
Solution Approach 1:
The patent uses lipid nanoparticles as intermediary carriers to deliver nucleic acids across cell membranes. The cationic lipids in the nanoparticle complex with anionic nucleic acids, forming protective complexes that facilitate cellular uptake while reducing direct toxicity of high-dose nucleic acid administration
Solution Approach 2:
The patent modifies the chemical structure of lipids and nucleic acids to change their physical-chemical parameters. Cationic lipids with specific charge densities and nucleic acid conjugates with modified properties enable effective delivery at lower doses, reducing toxicity while maintaining delivery efficacy
2Reliability
If conventional lipid nanoparticle formulations are used, then nucleic acid delivery is achieved, but transfection efficiency is insufficient and toxicity remains high
Solution Approach 1:
The patent employs composite lipid nanoparticle formulations combining multiple types of lipids (cationic, helper, PEGylated) with specific ratios. This composite approach enhances transfection efficiency by synergistic interactions among components while maintaining reduced toxicity through optimized composition
Solution Approach 2:
The patent introduces pH-sensitive polymers with specific functional groups (carboxylic acids, amines) that exhibit localized property changes at different pH levels. These polymers remain stable in circulation but become membrane-disruptive in the acidic endosomal environment, enabling efficient cytosolic delivery with minimal off-target effects
3Productivity
If pH-sensitive polymers are added to enhance delivery, then transfection efficiency is improved, but formulation complexity increases
Solution Approach 1:
The patent combines pH-sensitive polymers with lipid nanoparticles into a single integrated formulation. The polymer-lipid complex forms a unified delivery system where the polymer enhances the lipid nanoparticle's ability to escape endosomes, achieving improved transfection without requiring separate administration steps or complex multi-component systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer enhances the delivery of nucleic acids to the cytosol, improving transfection efficiency and reducing immune response, allowing for lower doses and increased stability of therapeutic agents.
Implementation Method 1
the polymer is stable under physiologic conditions, but undergoes a conformational change in response to pH variation that results in disruption of cellular membranes
Implementation Method 2
Internalization of the complex by the cell is followed by cytosolic delivery
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.